These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 38570694)

  • 1. RNAi-based drug design: considerations and future directions.
    Tang Q; Khvorova A
    Nat Rev Drug Discov; 2024 May; 23(5):341-364. PubMed ID: 38570694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA interference in the era of nucleic acid therapeutics.
    Jadhav V; Vaishnaw A; Fitzgerald K; Maier MA
    Nat Biotechnol; 2024 Mar; 42(3):394-405. PubMed ID: 38409587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic face of RNAi: in vivo challenges.
    Borna H; Imani S; Iman M; Azimzadeh Jamalkandi S
    Expert Opin Biol Ther; 2015 Feb; 15(2):269-85. PubMed ID: 25399911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA interference as a gene-specific approach for molecular medicine.
    Grünweller A; Hartmann RK
    Curr Med Chem; 2005; 12(26):3143-61. PubMed ID: 16375707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA Interference-Based Cancer Drugs: The Roadblocks, and the "Delivery" of the Promise.
    Das M; Musetti S; Huang L
    Nucleic Acid Ther; 2019 Apr; 29(2):61-66. PubMed ID: 30562145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development.
    Xie FY; Woodle MC; Lu PY
    Drug Discov Today; 2006 Jan; 11(1-2):67-73. PubMed ID: 16478693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNAi-based drug discovery and its application to therapeutics.
    Hokaiwado N; Takeshita F; Banas A; Ochiya T
    IDrugs; 2008 Apr; 11(4):274-8. PubMed ID: 18379962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular design and delivery of siRNA.
    Inoue A; Sawata SY; Taira K
    J Drug Target; 2006; 14(7):448-55. PubMed ID: 17062391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of RNA interference against cancer.
    Takeshita F; Ochiya T
    Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo application of RNA interference: from functional genomics to therapeutics.
    Lu PY; Xie F; Woodle MC
    Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The design and exogenous delivery of siRNA for post-transcriptional gene silencing.
    Gilmore IR; Fox SP; Hollins AJ; Sohail M; Akhtar S
    J Drug Target; 2004 Jul; 12(6):315-40. PubMed ID: 15545082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.
    Singh SK; Hajeri PB
    Drug Discov Today; 2009 Sep; 14(17-18):859-65. PubMed ID: 19540929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current state and future directions of RNAi-based therapeutics.
    Setten RL; Rossi JJ; Han SP
    Nat Rev Drug Discov; 2019 Jun; 18(6):421-446. PubMed ID: 30846871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies, design, and chemistry in siRNA delivery systems.
    Dong Y; Siegwart DJ; Anderson DG
    Adv Drug Deliv Rev; 2019 Apr; 144():133-147. PubMed ID: 31102606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. siRNA-based therapeutic approaches for rheumatic diseases.
    Apparailly F; Jorgensen C
    Nat Rev Rheumatol; 2013 Jan; 9(1):56-62. PubMed ID: 23090506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA interference (RNAi) in hematology.
    Scherr M; Steinmann D; Eder M
    Ann Hematol; 2004 Jan; 83(1):1-8. PubMed ID: 14574462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.